Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
88.21(c) 88.9(c) 88.89(c) 88.86(c) 88.97(c) Last
2 129 867 2 115 522 1 308 353 1 237 019 1 887 205 Volume
+1.98% +0.78% -0.01% -0.03% +0.12% Change
More quotes
Financials
Sales 2021 37 033 M 44 401 M 44 401 M
Net income 2021 5 909 M 7 085 M 7 085 M
Net Debt 2021 7 415 M 8 890 M 8 890 M
P/E ratio 2021 18,9x
Yield 2021 3,68%
Sales 2022 38 866 M 46 598 M 46 598 M
Net income 2022 6 979 M 8 368 M 8 368 M
Net Debt 2022 3 696 M 4 432 M 4 432 M
P/E ratio 2022 16,0x
Yield 2022 3,88%
Capitalization 111 B 135 B 133 B
EV / Sales 2021 3,21x
EV / Sales 2022 2,96x
Nbr of Employees 99 412
Free-Float 88,3%
More Financials
Company
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (71.2%): prescription drugs in the areas of general medicine (57.3% of net sales; mainly for the treatment of diabetes and cardiovascular diseases) and specialty medicine (42.7%; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune... 
Sector
Pharmaceuticals
Calendar
06/22Presentation
More about the company
Ratings of Sanofi
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about SANOFI
01:00pPRESS RELEASE DATED JUNE 11, 2021 : New pivotal data at EHA 2021 reinforces suti..
PU
04:08aER+/ HER2-VE BREAST CANCER PIPELINE : Emerging Therapies and Key pharma players ..
AQ
01:19aSANOFIá : Commits $52 Million, Other Guarantees For British Pension Scheme
MT
06/15SANOFIá : Berenberg reaffirms its Neutral rating
MD
06/15Belgian agri-tech firm Biotalys plans listing in Brussels
RE
06/14SANOFIá : - New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-cla..
AQ
06/14SANOFIá : provides update on Aubagio (teriflunomide) submission for children and..
AQ
06/11SANOFIá : Drug Blocks Red Blood Cell Destruction In Late-Stage Study
MT
06/11New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class invest..
GL
06/11SANOFIá : Multiple Sclerosis Drug Rejected By US FDA For Pediatric Population
MT
06/11SANOFIá : provides update on Aubagio« (teriflunomide) submission for children an..
PU
06/10SANOFIá : Receives a Buy rating from Goldman Sachs
MD
06/10Innate Pharma Molecule Shows Anti-Tumor Effect in Preclinical Studies
MT
06/10PRESS RELEASE : Pfizer and BioNTech to Provide 500 -3-
DJ
06/09GSK consumer arm confident that growth, cash flow will help with debt
RE
More news
News in other languages on SANOFI
06/11SANOFIá : données positives dans les agglutinines froides
06/11SANOFIá : Les nouvelles données pivots présentées au Congrès de l'EHA 2021 confi..
06/11MÄRKTE EUROPA/Gut behauptet - fallende Renditen stützen
06/10Aktien Europa Schluss: EZB-Sitzung und US-Inflation lassen Anleger kalt
06/10ORANGEá : création d'un accélérateur de startups, Futur4care
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 04/12
No turn-around in sight
BUY
More Stock Trading Analysis
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | MarketScreener
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 101,51 €
Last Close Price 88,97 €
Spread / Highest target 31,5%
Spread / Average Target 14,1%
Spread / Lowest Target -15,7%
EPS Revisions
Managers and Directors
NameTitle
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI13.05%134 782
JOHNSON & JOHNSON4.48%433 167
ROCHE HOLDING AG11.21%330 710
PFIZER, INC.6.76%221 613
NOVARTIS AG0.77%210 689
ABBVIE INC.7.82%204 582